Last reviewed · How we verify
TIL + IL2
TIL + IL-2 combines tumor-infiltrating lymphocytes with interleukin-2 to expand and activate patient-derived T cells for adoptive cell therapy against cancer.
TIL + IL-2 combines tumor-infiltrating lymphocytes with interleukin-2 to expand and activate patient-derived T cells for adoptive cell therapy against cancer. Used for Metastatic melanoma, Advanced solid tumors.
At a glance
| Generic name | TIL + IL2 |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Adoptive cell therapy; T cell immunotherapy |
| Target | IL-2 receptor; tumor-associated antigens |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tumor-infiltrating lymphocytes (TILs) are harvested from a patient's own tumor, expanded ex vivo, and reinfused along with interleukin-2 (IL-2) to enhance T cell proliferation and activation. IL-2 acts as a growth factor to support the expansion and persistence of these tumor-reactive T cells, enabling them to recognize and eliminate cancer cells.
Approved indications
- Metastatic melanoma
- Advanced solid tumors
Common side effects
- Cytokine release syndrome
- Fever
- Hypotension
- Fatigue
- Injection site reactions
Key clinical trials
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (PHASE2)
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (PHASE2)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (PHASE1)
- LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (PHASE2)
- A Phase II Trial of LM103 in Advanced Melanoma (PHASE2)
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (PHASE1)
- A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIL + IL2 CI brief — competitive landscape report
- TIL + IL2 updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI